趙 珮雯

Medicine & Life Sciences

1. Sepsis 100%
2. Confidence Intervals 72%
3. Taiwan 70%
4. Cohort Studies 69%
5. Survivors 64%
6. National Health Programs 62%
7. Chronic Kidney Failure 56%
8. Hydroxymethylglutaryl-CoA Reductase Inhibitors 53%
9. Mortality 52%
10. Tuberculosis 51%
11. Population 46%
12. Angiotensin Receptor Antagonists 46%
13. Angiotensin-Converting Enzyme Inhibitors 40%
14. Hyperkalemia 40%
15. Human Influenza 38%
16. Stroke 37%
17. Propensity Score 37%
18. Databases 34%
19. Longitudinal Studies 34%
20. Case-Control Studies 33%
21. Myocardial Infarction 32%
22. Pyogenic Liver Abscess 31%
23. Methylmalonic acidemia 31%
24. Hospitalization 31%
25. Dipeptidyl-Peptidase IV Inhibitors 31%
26. Acute Kidney Injury 30%
27. Dialysis 26%
28. Patient-Controlled Analgesia 26%
29. Influenza Vaccines 26%
30. Acute Cholecystitis 25%
31. Metformin 25%
32. Cardiac Arrhythmias 24%
33. Drug-Eluting Stents 24%
34. Myasthenia Gravis 24%
35. Systemic Scleroderma 23%
36. Platelet Aggregation Inhibitors 23%
37. Appendicitis 23%
38. Renal Dialysis 22%
39. Odds Ratio 22%
40. Endocarditis 21%
41. Risk Reduction Behavior 21%
42. Type 2 Diabetes Mellitus 20%
43. Vaccination 20%
44. Heart Failure 20%
45. Chronic Renal Insufficiency 18%
46. Pharmaceutical Preparations 18%
47. Fibric Acids 18%
48. Intensive Care Units 18%
49. Pulmonary Tuberculosis 17%